main content start
Showing Results for: “exercise”
Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk
The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular
Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (β-cell) Function During and After Treatment
In a study measuring Beta-cell (β-cell) function in adults with impaired glucose tolerance (IGT) or newly diagnosed type 2 diabetes (T2D), researchers from the Restoring Insulin Secretion (RISE) Adult Medication Study found β-cell function was improved during active treatment but did not produce any lasting benefits after treatment cessation. Results presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® suggest continued intervention may be required to alter progressive β-cell dysfunction. Given the increased recognition of the critical role
Insulin-Producing Beta Cells Are Not Irreversibly Lost in Early Type 2 Diabetes
Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal function through the removal of excess fat in the cells, according to a study entitled “Remission of Type 2 Diabetes for Two Years Is Associated with Full Recovery of Beta-Cell Functional Mass in the Diabetes Remission Clinical Trial (DiRECT)” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. More than one-third (36%) of the participants who took part in an
Food and Blood Glucose
Make your food work for your blood glucose. Blood glucose highs and lows can be frustrating. Find out how to get a better handle on things and stay even.
Eye Health Resources
Access information and resources on diabetes-related eye disease, prevention, and treatment.
Discover the Power of Diabetes Support
Join our community and find the support you need to thrive with diabetes. Explore fundraisers, summer camps, and more in your local community.
Honor a Loved One
Honor someone special in your life by making a lifesaving gift to the American Diabetes Association (ADA) in their name
Give Today and Change lives!
With your support, the American Diabetes Association® can continue our lifesaving work to make breakthroughs in research and provide people with the resources they need to fight diabetes.